EA200400174A1 - Трансгенные растения, экспрессирующие кобаламинсвязывающие белки - Google Patents

Трансгенные растения, экспрессирующие кобаламинсвязывающие белки

Info

Publication number
EA200400174A1
EA200400174A1 EA200400174A EA200400174A EA200400174A1 EA 200400174 A1 EA200400174 A1 EA 200400174A1 EA 200400174 A EA200400174 A EA 200400174A EA 200400174 A EA200400174 A EA 200400174A EA 200400174 A1 EA200400174 A1 EA 200400174A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cobalamin
cobalamins
corrin
transgenic plants
cobalt atom
Prior art date
Application number
EA200400174A
Other languages
English (en)
Inventor
Ларс Эрик Берлунд
Торбен Эллебаек Петерсен
Сергей Николаевич Федосов
Эбба Нексо
Ниельс Беч Лаурсен
Эрик Остергаард Йенсен
Original Assignee
Кобенто Биотек А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кобенто Биотек А/С filed Critical Кобенто Биотек А/С
Publication of EA200400174A1 publication Critical patent/EA200400174A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)

Abstract

В общем, настоящее изобретение относится к получению рекомбинантных белков, которые могут связывать кобаламин из трансгенных растений. Рекомбинантные белки могут использоваться в целях профилактики и/или терапии при лечении дефицита кобаламина и при аналитических исследованиях. В настоящем изобретении предложено трансгенное растение, которое экспрессирует по крайней мере один белок, способный связывать кобаламин и/или его аналоги. "Кобаламин" (Cbl) - молекула, которая состоит из кольца коррина с четырьмя звеньями пиррола, которые окружают атом кобальта, расположенный в центре, и образуют с ним связи. Ниже плоскости коррина располагается производная нуклеотида с диметилбензимидазольным основанием, которое также связано с атомом кобальта. Наконец атом кобальта образует связи с шестой молекулой (например, -CH, OH-, HO, 5'-деоксиаденозил, CN), расположенной над плоскостью коррина. Цианокобаламин упоминается как витамин B12, но другие кобаламины имеют идентичные пищевые свойства.Отчет о международном поиске был опубликован 2003.07.24.
EA200400174A 2001-07-13 2002-07-12 Трансгенные растения, экспрессирующие кобаламинсвязывающие белки EA200400174A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0117171A GB2377446B (en) 2001-07-13 2001-07-13 Expression of cobalamin binding proteins in transgenic plants
PCT/GB2002/003227 WO2003006661A2 (en) 2001-07-13 2002-07-12 Transgenic plants expressing cobalamin binding proteins

Publications (1)

Publication Number Publication Date
EA200400174A1 true EA200400174A1 (ru) 2005-06-30

Family

ID=9918480

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400174A EA200400174A1 (ru) 2001-07-13 2002-07-12 Трансгенные растения, экспрессирующие кобаламинсвязывающие белки

Country Status (16)

Country Link
US (5) US20040268440A1 (ru)
EP (1) EP1417320A2 (ru)
JP (1) JP2004533851A (ru)
KR (1) KR20040027876A (ru)
CN (1) CN1549862A (ru)
BR (1) BR0211130A (ru)
CA (1) CA2453574A1 (ru)
EA (1) EA200400174A1 (ru)
GB (1) GB2377446B (ru)
HU (1) HUP0400458A3 (ru)
IL (1) IL159817A0 (ru)
MX (1) MXPA04000377A (ru)
NZ (1) NZ531026A (ru)
PL (1) PL367827A1 (ru)
WO (1) WO2003006661A2 (ru)
ZA (1) ZA200400751B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782063A2 (en) * 2004-07-29 2007-05-09 Cobento Biotech A/S Methods for determining proteins and protein-bound compounds comprising enzymatic modification
US7790363B2 (en) * 2005-02-07 2010-09-07 Abbott Laboratories Inc. Diagnostic test for vitamin B12
US20170254819A1 (en) * 2014-09-15 2017-09-07 Nestec S.A. Method for determining vitamin b12 uptake
WO2016187499A1 (en) 2015-05-20 2016-11-24 Syracuse University Improved glycemic control using intrinsic factor bound to a vitamin b12 conjugate of a glucagon-like peptide- 1 receptor agonist
US10716827B2 (en) 2015-05-20 2020-07-21 Syracuse University Compositions and methods for enhancing peptide stability against protease digestion
WO2020236903A1 (en) * 2019-05-20 2020-11-26 Syracuse University Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206
WO2021030166A1 (en) * 2019-08-09 2021-02-18 Siemens Healthcare Diagnostics Inc. Anti-hog tcn1 monoclonal antibodies and methods of production and use thereof
WO2023089616A1 (en) * 2021-11-18 2023-05-25 Imagindairy Ltd. Food compositions comprising recombinant cells comprising transcobalamin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591678A (en) * 1969-09-05 1971-07-06 American Cyanamid Co Method of purifying intrinsic factor
US4279886A (en) * 1979-01-02 1981-07-21 University Patents, Inc. Test for pancreatic exocrine function
SU1751207A1 (ru) 1990-04-20 1992-07-30 Институт общей генетики им.Н.И.Вавилова Рекомбинантна плазмидна ДНК pST20, кодирующа альфа-интерферон человека в растени х табака
JPH0549478A (ja) * 1991-06-06 1993-03-02 Kanegafuchi Chem Ind Co Ltd ヒト内因子をコードするｄｎａ配列
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5939288A (en) * 1995-06-07 1999-08-17 Iowa State University Research Foundation, Inc. Plant secretory signal peptides and nectarins
US5959187A (en) * 1996-09-26 1999-09-28 Bailey; James E. Expression of oxygen-binding proteins in plants
EP1230257A4 (en) * 1998-12-23 2003-08-13 Thompson Boyce Plant Res EXPRESSION OF IMMUNOGENOUS HEPATITIS B SURFACE ANTIGEN IN TRANSGENIC PLANTS
ES2288882T3 (es) * 1999-10-26 2008-02-01 Plant Research International B.V. Glicosilacion de tipo mamifero en plantas.
CN1301718A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——钴胺素结合蛋白10和编码这种多肽的多核苷酸
AU2002244071A1 (en) * 2001-02-14 2002-08-28 Ventria Bioscience Expression system for seed proteins
ATE472605T1 (de) * 2005-07-12 2010-07-15 Greenovation Biotech Gmbh Verbesserungen der proteinproduktion oder in zusammenhang damit

Also Published As

Publication number Publication date
GB2377446B (en) 2005-06-29
WO2003006661A3 (en) 2003-07-24
JP2004533851A (ja) 2004-11-11
US20150158922A1 (en) 2015-06-11
US20100184642A1 (en) 2010-07-22
US9751918B2 (en) 2017-09-05
HUP0400458A3 (en) 2005-06-28
IL159817A0 (en) 2004-06-20
MXPA04000377A (es) 2005-03-07
BR0211130A (pt) 2004-10-26
PL367827A1 (en) 2005-03-07
GB2377446A (en) 2003-01-15
EP1417320A2 (en) 2004-05-12
NZ531026A (en) 2005-09-30
US20150158920A1 (en) 2015-06-11
US20150157731A1 (en) 2015-06-11
CN1549862A (zh) 2004-11-24
ZA200400751B (en) 2005-04-29
GB0117171D0 (en) 2001-09-05
HUP0400458A2 (hu) 2004-11-29
CA2453574A1 (en) 2003-01-23
KR20040027876A (ko) 2004-04-01
WO2003006661A2 (en) 2003-01-23
US20040268440A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
CY1119127T1 (el) Επιτοποι σκληροστινης
EP1408986A4 (en) PROTEOMIMETIC COMPOUNDS AND CORRESPONDING METHODS
MXPA05007853A (es) Antagonistas de il-1 beta humana.
TW200505480A (en) High concentration antibody and protein formulations
WO2002069886A3 (en) Modified proteins, designer toxins, and methods of making thereof
ME00185B (me) Specifični agensi koji vezuju humani angiopoetin-2
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
EA200400174A1 (ru) Трансгенные растения, экспрессирующие кобаламинсвязывающие белки
DK1930439T3 (da) Neurotrofe faktorer
DE60119853D1 (de) Kristallstruktur von Ribosomen und Proteinsynthese-Inhibitoren
HK1076055A1 (en) Covalent conjugates between artemisinin-related endoperoxides and iron- carrying proteins and methods of use
EP0506821A4 (en) Hybrid protein c
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
EA200300066A1 (ru) Производные аминоалкоксибензоил-бензофурана или бензотиофена, способ их получения и содержащие их композиции
ES2100960T3 (es) Estructura proteica de la toxina vegetal gelonina.
ES2092067T3 (es) Procedimiento de purificacion de una proteina altamente glicosilada.
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
DE69935071D1 (de) Mutein von humanem Thrombopoietin
NO20020329L (no) Antitumor-antistoffer, proteiner og anvendelse derav
DE60104866D1 (de) Aminoalkenylbenzoyl-benzofurane oder benzothiophene, verfahren zur ihrer herstellung und sie enthaltende zubereitungen
WO2004110367A3 (en) Sdr proteins from staphylococcus capitis and their use in preventing and treating infections